1. Home
  2. SGLY vs CDT Comparison

SGLY vs CDT Comparison

Compare SGLY & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Singularity Future Technology Ltd.

SGLY

Singularity Future Technology Ltd.

HOLD

Current Price

$0.63

Market Cap

3.4M

Sector

N/A

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.71

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGLY
CDT
Founded
2001
2019
Country
United States
United States
Employees
N/A
6
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
2.9M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
SGLY
CDT
Price
$0.63
$1.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
86.3K
410.7K
Earning Date
11-14-2025
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,619,679.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.48
52 Week High
$5.49
$2,198.40

Technical Indicators

Market Signals
Indicator
SGLY
CDT
Relative Strength Index (RSI) 46.83 43.88
Support Level $0.56 $1.69
Resistance Level $0.65 $1.89
Average True Range (ATR) 0.05 0.25
MACD 0.01 0.01
Stochastic Oscillator 44.19 30.86

Price Performance

Historical Comparison
SGLY
CDT

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: